Epoxy resins and coatings contain BADGE (Bisphenol A diglycidyl ether) and derivatives that migrate into contacted substances creating endocrine disruption concerns requiring sensitive detection distinguishing BADGE from related compounds. BADGE (Bisphenol A diglycidyl ether) analysis by GC-MS targets epoxy components that migrate from coatings and adhesives with methodology preventing hydrolysis while ensuring complete detection. Careful handling prevents BADGE hydrolysis to hydroxylated derivatives during analysis, derivatization ensures complete detection of BADGE and transformation products, and chromatographic separation distinguishes BADGE from structurally similar compounds. Critical for devices with epoxy adhesives requiring validation that curing adequately reacts BADGE preventing migration, coated metal components where epoxy linings protect contents but potentially release BADGE, and demonstrating compliance with restrictions on bisphenol-related compounds increasingly targeted by regulations. For medical devices using epoxy coatings in fluid pathways, BADGE testing validates that coating formulation and cure conditions minimize residual monomers, migration under simulated use remains below regulatory limits, and aging doesn't increase BADGE release through coating degradation. The analysis accommodates various BADGE derivatives including hydrolyzed products formed during migration or storage, quantifies both BADGE monomers and higher molecular weight oligomers, and supports risk assessment calculating exposure from measured levels. Manufacturing validation confirms epoxy curing achieves adequate BADGE reaction, coating application processes don't introduce excess BADGE through incomplete mixing, and quality control detects batches with elevated BADGE requiring corrective action. The testing supports "BPA-free" claims by confirming epoxy alternatives don't introduce BADGE or similar bisphenol-derived epoxy compounds with comparable endocrine activity concerns.